Spravato: New Treatment For Depression

By Colleen Blanchfield, MD

Full Circle Neuropsychiatric Wellness Center

. http://www.cblanchfieldmd.com

More Mental Health Articles

Spravato: New Treatment For Depression

Although we have come far in our understanding of the brain, much still remains unknown. Through research and development, there have been significant strides in understanding mental health disorders and how to treat them.

In the United States, major depressive disorder (MDD) is a common mental health disorder affecting 16.2 million Americans annually. Patients with depression may need several trials of antidepressants before achieving a positive response. Of those who seek treatment, only 60% will respond to medication and many of those will require trials of several medication before experiencing remission. The 40% of patients who do not respond to medications are considered to have treatment resistant depression (TRD). These patients will continue to experience symptoms of sadness, decreased motivation and energy levels, and persistent thoughts of death or suicide.

Treatment resistant depression affects the outcomes of other medical conditions and reduces life expectancy. It is a leading cause of disability in the United States and worldwide. For years psychiatrist have struggled to help these patients.

In March 2019, the FDA approved esketamine, (sold under the brand name Spravato^®) for patients with TRD. Esketamine has a novel mechanism of action to offer patients relief from depression. It is self-administered via non-invasive intranasal dosing in a physician’s office. It is given in conjunction with routine antidepressant medications.

Many patients who have tried esketamine report they feel more like themselves again. They note improvement in focus, energy, and describe marked improvements in mood. Patients describe improved interest and participation in activities with friends and family.

Patients who have tried and failed at least two antidepressants medication are potentially eligible for this medication. Patients who feel that they have TRD and are interested in esketamine treatments, should contact a local certified Spravato treatment center for information.